NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus

Summary 1. In the present study, we investigated the associations of nicotinamide phosphoribosyltransferase (NAMPT)‐3186 C/T and ‐948G/T polymorphisms with the risk of Type 2 diabetes mellitus (T2DM) and their impact on the efficacy of repaglinide in Chinese Han T2DM patients. 2. In all, 170 patient...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental pharmacology & physiology 2011-08, Vol.38 (8), p.550-554
Main Authors: Sheng, Fei-Feng, Dai, Xing-Ping, Qu, Jian, Lei, Guang-Hua, Lu, Hong-Bin, Wu, Jing, Xu, Xiao-Jing, Pei, Qi, Dong, Min, Liu, Ying-Zi, Zhou, Hong-Hao, Liu, Zhao-Qian
Format: Article
Language:English
Subjects:
Adult
Aged
Alleles
Asian Continental Ancestry Group - genetics
Carbamates - pharmacology
Carbamates - therapeutic use
Cholesterol - blood
Cholesterol - metabolism
Control Groups
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - genetics
efficacy
Female
Genetic Predisposition to Disease - ethnology
Genotype
Humans
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Insulin - blood
Insulin - metabolism
Male
Middle Aged
nicotinamide phosphoribosyltransferase
Nicotinamide Phosphoribosyltransferase - genetics
Piperidines - pharmacology
Piperidines - therapeutic use
polymorphism
Polymorphism, Genetic
Polymorphism, Single Nucleotide
repaglinide
Treatment Outcome
Type 2 diabetes
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary 1. In the present study, we investigated the associations of nicotinamide phosphoribosyltransferase (NAMPT)‐3186 C/T and ‐948G/T polymorphisms with the risk of Type 2 diabetes mellitus (T2DM) and their impact on the efficacy of repaglinide in Chinese Han T2DM patients. 2. In all, 170 patients with T2DM and 129 healthy controls were genotyped for NAMPT‐948G>T and ‐3186C>T polymorphisms. Thirty‐five patients with different NAMPT ‐3186 C/T genotypes and the same organic anion‐transporting polypeptide 1B1 (OATP1B1521) T/C genotype were randomly selected to undergo 8 weeks preprandial repaglinide treatment (1 mg, three times daily). Serum fasting plasma glucose (FPG), post‐prandial plasma glucose (PPG), glycated haemoglobin (HbAlc), fasting serum insulin (FINS), post‐prandial serum insulin (PINS), triglyceride (TG), total cholesterol (CHO), homeostasis model assessment of insulin resistance (HOMA‐IR), low‐density lipoprotein–cholesterol (LDL‐C) and high‐density lipoprotein–cholesterol (HDL‐C) were determined before and after repaglinide treatment. 3. After repaglinide treatment for 8 consecutive weeks, there were significantly decreases in PFG, PPG, HbAlc, CHO and LDL‐C, and increases in FINS, HDL‐C and the HDL‐C : LDL‐C ratio, in T2DM patients. The elevated PINS value in patients with CT genotypes was significantly lower than that in patients with the CC and TT genotypes (P 
ISSN:0305-1870
1440-1681
DOI:10.1111/j.1440-1681.2011.05548.x